(Total Views: 1021)
Posted On: 05/07/2019 9:32:54 AM
Post# of 594
NEWS!!!
HENDERSON, Nev., May 07, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), ("UHP" or the "Company"
, manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that IQVIA has completed its independent market assessment of certain market opportunities for HemoStyp. This survey used a combination of interviews, market data and product usage reports to create a detailed outlook for HemoStyp's revenue potential assuming, among other factors, the receipt of FDA approval for Class III surgical applications. The primary purpose of the study is to assist the Company in its previously announced Review of Strategic Alternatives. On April 30th, IQVIA made a formal presentation to UHP management and its financial advisor, Société Générale. (https://www.unitedhealthproductsinc.com/press-releases/2018/11/28/united-health-products-united-health-engages-socit-gnrale-to-undertake-strategic-review).
HENDERSON, Nev., May 07, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), ("UHP" or the "Company"
, manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that IQVIA has completed its independent market assessment of certain market opportunities for HemoStyp. This survey used a combination of interviews, market data and product usage reports to create a detailed outlook for HemoStyp's revenue potential assuming, among other factors, the receipt of FDA approval for Class III surgical applications. The primary purpose of the study is to assist the Company in its previously announced Review of Strategic Alternatives. On April 30th, IQVIA made a formal presentation to UHP management and its financial advisor, Société Générale. (https://www.unitedhealthproductsinc.com/press-releases/2018/11/28/united-health-products-united-health-engages-socit-gnrale-to-undertake-strategic-review).
(0)
(0)
